Loading...
XLON
0OO9
Market cap57bUSD
Oct 21, Last price  
41.23EUR
Name

Fresenius SE & Co KGaA

Chart & Performance

D1W1MN
P/E
25.77
P/S
1.06
EPS
1.60
Div Yield, %
—
Shrs. gr., 5y
0.21%
Rev. gr., 5y
-9.22%
Revenues
21.83b
-2.09%
7,889,000,00010,777,000,00011,358,000,00012,336,000,00014,164,000,00015,972,000,00016,522,000,00019,290,000,00020,331,000,00023,231,000,00027,626,000,00029,083,000,00033,886,000,00033,530,000,00035,409,000,00036,277,000,00037,520,000,00040,840,000,00022,299,000,00021,833,000,000
Net income
901m
P
222,000,000330,000,000410,000,000270,000,000991,000,0001,205,000,0001,328,000,000926,000,0001,011,000,0001,067,000,0001,358,000,0001,593,000,0001,814,000,0002,027,000,0001,883,000,0001,707,000,0001,818,000,0001,372,000,000-594,000,000901,000,000
CFO
2.45b
-45.09%
780,000,0001,052,000,0001,296,000,0001,074,000,0001,553,000,0001,911,000,0001,689,000,0002,438,000,0002,320,000,0002,585,000,0003,327,000,0003,574,000,0003,937,000,0003,742,000,0004,263,000,0006,549,000,0005,078,000,0004,198,000,0004,456,000,0002,447,000,000

Profile

Fresenius SE & Co. KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, hemodialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of therapy and care ill patients. This segment offers IV drugs, including intravenously administered generic drugs for oncology, anesthetics, analgesics, anti-infectives, and critical care; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; biosimilars, a biological medicine for autoimmune and oncology diseases; medical devices and disposal used to administer IV generic drugs, infusion therapies, and clinical nutrition products; and transfusion products for collection of blood components and corporeal therapies. The Fresenius Helios segment operates 90 hospitals, approximately 130 outpatient clinics, and 6 prevention centers in Germany; and 49 hospitals, 88 outpatient clinics, and approximately 300 risk prevention centers in Spain. This segment also provides services in the field of fertility treatments through 33 clinics and additional 39 sites across 10 countries on 3 continents. The Fresenius Vamed segment manages projects and offers services for hospitals and other health care facilities. This segment provides project development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.
URL
https://www.fresenius.com/
IPO date
Dec 18, 1986
Employees
315,233
Domiciled in
DE
Incorporated in
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
21,833,000
-2.09%
22,299,000
-45.40%
40,840,000
8.85%
Cost of revenue
20,015,000
21,057,000
37,726,000
Unusual Expense (Income)
NOPBT
1,818,000
1,242,000
3,114,000
NOPBT Margin
8.33%
5.57%
7.62%
Operating Taxes
521,000
477,000
697,000
Tax Rate
28.66%
38.41%
22.38%
NOPAT
1,297,000
765,000
2,417,000
Net income
901,000
-251.68%
(594,000)
-143.29%
1,372,000
-24.53%
Dividends
(550,000)
(403,000)
Dividend yield
Proceeds from repurchase of equity
20,000
BB yield
Debt
Debt current
2,772,000
2,581,000
3,036,000
Long-term debt
12,305,000
15,247,000
31,319,000
Deferred revenue
31,000
40,000
23,000
Other long-term liabilities
2,788,000
2,483,000
4,120,000
Net debt
13,583,000
11,710,000
30,888,000
Cash flow
Cash from operating activities
2,447,000
4,456,000
4,198,000
CAPEX
(923,000)
(1,134,000)
(1,917,000)
Cash from investing activities
(510,000)
(3,187,000)
(2,607,000)
Cash from financing activities
(2,183,000)
(1,377,000)
(1,604,000)
FCF
10,194,000
10,534,000
1,272,000
Balance
Cash
1,494,000
2,562,000
2,345,000
Long term investments
3,556,000
1,122,000
Excess cash
402,350
5,003,050
1,425,000
Stockholders' equity
18,827,000
15,325,000
27,895,000
Invested Capital
36,283,650
33,000,950
62,185,000
ROIC
3.74%
1.61%
4.04%
ROCE
4.87%
3.22%
4.77%
EV
Common stock shares outstanding
563,237
563,237
561,264
Price
Market cap
EV
EBITDA
3,022,000
2,720,000
6,087,000
EV/EBITDA
Interest
547,000
534,000
694,000
Interest/NOPBT
30.09%
43.00%
22.29%